Case Reports in Infectious Diseases

Case Reports in Infectious Diseases / 2015 / Article

Case Report | Open Access

Volume 2015 |Article ID 905920 |

Hao H. Nguyen, Nada Fadul, Muhammad S. Ashraf, Dawd S. Siraj, "Osteomyelitis Infection of Mycobacterium marinum: A Case Report and Literature Review", Case Reports in Infectious Diseases, vol. 2015, Article ID 905920, 5 pages, 2015.

Osteomyelitis Infection of Mycobacterium marinum: A Case Report and Literature Review

Academic Editor: Oguz R. Sipahi
Received20 Oct 2014
Accepted11 Dec 2014
Published18 Jan 2015


Mycobacterium marinum (M. marinum) is a ubiquitous waterborne organism that grows optimally at temperatures around 30°C. It is a nontuberculous Mycobacterium found in nonchlorinated water with worldwide prevalence. It is the most common atypical Mycobacterium that causes opportunistic infection in humans. M. marinum can cause superficial infections and localized invasive infections in humans, with the hands being the sites most frequently affected. It can cause skin lesions, which are either single, papulonodular lesions, confined to an extremity, or may resemble cutaneous sporotrichosis. This infection can also cause deeper infections including tenosynovitis, bursitis, arthritis, and osteomyelitis. Disseminated infections and visceral involvements have been reported in immunocompromised patients. We here report a case of severe deep soft tissue infection with necrotizing fasciitis and osteomyelitis of the left upper extremity (LUE) caused by M. marinum in an immunocompromised patient.

1. Introduction

Mycobacterium marinum was first isolated in 1926 by Aronson from salt water fish carcasses in the Philadelphia aquarium [1]. Baker and Hagan discovered that the mycobacterium caused tuberculosis in fresh water platyfish and called it M. platypoecilus [2]. In 1951, it was recognized as a human pathogen by Linell and Norden who isolated it from the skin lesions of swimmers from the swimming pool in Sweden [3].

M. marinum is a nontuberculous mycobacterium belonging to Runyon group I, a photochromogen [4]. M. marinum has a worldwide distribution and primarily infects fish that can secondarily contaminate aquaria, swimming pools, rivers, and seawater. When transmitted to animals such as amphibians, fish, mice, and bats, it can be highly prevalent in fish tanks and cause infections and death in various fish species [4]. The colonies form a yellow pigment when the culture medium on which they are growing is exposed to light. Optimal growth is at 30 to 32°C. It grows slowly or not at all at 37°C. This organism will grow nicely on standard mycobacterial media and produces smooth and shiny colonies in an average of 10 to 28 days, though the cultures should be held for 6 weeks if negative. M. marinum preferentially grows at cold temp between 30 to 32°C and thus, infections with M. marinum are usually localized primarily to the skin. Less commonly it extends to involve deeper structures such as joints and tendons. Dissemination has been reported, but is distinctly unusual [5]. In general, M. marinum infection in humans is comparatively rare. The approximate annual incidence in the United States is 0.27 confirmed cases per 100,000 inhabitants [6]. In 90% of cases, infection takes place via trauma to the upper extremity and is not transmittable from person to person [7].

We searched the published English literature for cases of severe deep soft tissue infection and osteomyelitis caused by M. marinum both in immunocompromised and immunocompetent individuals. We found eleven published cases of adult M. marinum complicated with osteomyelitis. Four of them had compromised immune systems. This case review aims to focus on severe deep soft tissue infection and osteomyelitis caused by M. marinum.

2. Case Report

Patient is a 64-year-old Caucasian male presented to the emergency room at the end of December at our facility with worsening left arm swelling. Two weeks ago, he was initially admitted for the right arm swelling and tenderness. He, at baseline, has been on leflunomide for three years for treatment of rheumatoid arthritis and previously was on prednisone for the same reason. Patient reported that, in mid-November, he started to experience significant pain in both wrists and was evaluated at the rheumatologist office for possible rheumatoid arthritis flare. He had received steroid injections in bilateral wrists. During his first admission two weeks prior, he was diagnosed with deep abscesses of right upper extremity (RUE) which has later gotten incision and drainage. At that time, only bacterial cultures were sent, which grew methicillin-sensitive Staphylococcus aureus. Patient was discharged home on trimethoprim/sulfamethoxazole oral tablets but readmitted seven days later with pain and pustules now mainly on all of the fingers of the left forearm (Figure 1).

He again underwent drainage and bacterial and acid fast bacilli smear and cultures were sent. M. marinum was identified phenotypically in our lab when the culture grew at 30 degrees Celsius. The sample was also sent out for biochemical sequence and further identified as M. marinum (Nichols Institute, Chantilly, VA). He was empirically treated with intravenous imipenem, linezolid, and azithromycin. During this second admission, magnetic resonance imaging (MRI) of the left arm was done which showed multiple ulcerations extending from the skin surface into the subcutaneous fat with the largest visualized at the palmar aspect of the wrist, extending deep to the level of the carpal tunnel/hook of the hamate, at the dorsal and ulnar aspects of the mid- and distal forearm at two sites and at the ulnar aspect of the distal forearm suggesting tenosynovitis with necrotizing fasciitis. He recovered well from the surgery and was discharged on doxycycline and azithromycin while waiting for susceptibility. Despite being adherent to this regimen for four weeks, he was ultimately readmitted a third time with new abscess formation on medial aspect of his proximal LUE and repeated MRI showing osteomyelitis of the left distal ulna (Figure 2). Susceptibility test with minimal inhibitor concentration (MIC) (Focus Diagnostics, Inc., Cypress, CA) came back with M. marinum resistant to doxycycline and rifampin (Table 1). He underwent the third incision and drainage with the skin graft for his LUE. Therapy was then changed to azithromycin and trimethoprim/sulfamethoxazole based on the susceptibility result (Table 1). Because of extensive disease and slow improvement on therapy, our patient received nine months of antibiotics therapy with good response (Figure 3). He is still being followed by infectious diseases and plastic surgery.

OrganismM. marinum with minimal inhibitory concentration (MIC) values

Amikacin8 susceptible (S)
Ciprofloxacin8 resistance (R)
Clarithromycin2 S
Doxycycline16 R
Ethambutol4 S
Moxifloxacin4 R
Rifampin2 R
Rifabutin ≤0.25 S
Trimethoprim/sulfamethoxazole2/38 S

3. Methods

We searched the English language literature published until August 2014 in the PubMed database. Relevant studies were identified using various key word combinations including “mycobacterium,” “marinum,” “osteomyelitis,” and “treatment.” No lower publication date limit was set. Eleven published cases of Mycobacterium marinum osteomyelitis were ascertained. The clinical characteristics including age, gender, predisposing factors, duration of therapy, clinical outcome, and list of antimicrobials used were summarized in Table 2.

AuthorYearAgeSexImmune statusOM siteSource Chemotherapy + surgical debridementDurationOutcome

Jolly and Seabury [8]1972136MNormalFingerFishingNoneN/aAmputation
Wendt et al. [9]1986147FNormalFingerUnknownINH, rifampin, and ethambutol3 weeksAmputation
Clark et al. [10]1990156MNormalFingerFishing/steroid injectionMinocycline, rifampin, and ethambutol9 monthsRecovered
Vazquez and Sobel [11]1992162FNormalFingerFish tankINH, rifampin, and bactrim3 weeksAmputation
Harth et al. [12]1994156MNormalFingerFish tank/steroid injectionCiprofloxacin, ethambutol, and rifampin12 monthsRecovered
Alloway et al. [13]1995171MNormalFingerFishingCiprofloxacin, ethambutol, and rifampin12 monthsRecovered
Barton et al. [14]1997148FDeficientFingerFish tankDoxycycline6 monthsRecovered
Shih et al. [15]1997152FNormalFingerFish dealerClarithromycin and ethambutol18 monthsRecovered
Wilson et al. [16]2003147MDeficientFoot (talus)NoneRifabutin and ciprofloxacin3 monthsAmputation
Sivan et al. [17]2008166MDeficientLegFish tankRifampicin, ethambutol, and moxifloxacin12 monthsRecovered
Present case2014164MDeficientArmFishingAzithromycin and bactrim9 monthsRecovered

Barton et al., 1997 [14]: immunosuppressive therapy for rheumatoid arthritis and fibrosing alveolitis.
Wilson et al., 2003 [16]: acquired immunodeficiency syndrome.
Sivan et al., 2008 [17]: immunosuppressive therapy for bullous pemphigoid.
Present-2014: immunosuppressive therapy for rheumatoid arthritis.

4. Discussion

Mycobacterium marinum is a nontuberculous mycobacterium belonging to Runyon group I, a photochromogen. From the literature review, its infection occurs approximately about 2–6 weeks after direct inoculation of the organism either from fish fins and bites or from the handling of aquariums. Incubation period is normally about 2–6 weeks. However, there are some cases reporting an incubation time of 2 to 4 months and longer, with some cases reporting an incubation period as long as 9 months due to the slow-growing nature of this organism [6].

There are many different clinical presentations of M. marinum infection. In immunocompetent patient, most commonly it appears as a solitary papulonodular lesion on an extremity. In particular, these lesions tend to occur over a prominence that has a predisposition to be abraded, such as finger, hand, or knee. A history of preceding minor trauma is common and an occupation or hobby that resulted in a likely environmental water exposure is the rule [18]. Inflammatory nodules or abscesses can develop in severely immunosuppressed patient, usually in a sporotrichotic type of distribution [3]. This “sporotrichoid” disease begins with distal inoculation and may lead to the development of nodular lymphangitis. Over a period of months, localized cutaneous disease can spread to deeper soft tissues, causing tenosynovitis, arthritis, bursitis, and/or osteomyelitis of the underlying bone; it can also be life-threatening, and lesions may or may not be painful [6]. Infections with M. marinum can be theoretically classified into four different clinical categories to help in guiding treatment options. Type I includes single or limited (1–3 lesions) superficial cutaneous infections (ulcerated, crusted, or verrucous plaques or nodules). Type II includes numerous (>3) lesions in a sporotrichoid distribution pattern or with inflammatory nodules, abscesses, and granulomas. Type III includes deep infections with or without skin involvement, including tenosynovitis, arthritis, bursitis, and/or osteomyelitis and Type IV refers to disseminated infection, lung involvement, and other systemic manifestations. Bacteremia is usually seen in immunocompromised patients but is considered very rare [19, 20]. Our case was the clinical manifestation of Type III infection.

In the literature, there are eleven cases where M. marinum presented with deep tissue infection and osteomyelitis. The first case was published in 1972 involving a 36-year-old healthy Vietnamese female who was exposed to salt water and fishing presented with deep infection and osteomyelitis of the hand leading to amputation. Among the eleven cases, there were seven cases of immunocompetent patients and four cases with underlined immunocompromised status as listed in Table 1. The majority of infections involved the upper extremities. Ten out of eleven cases were treated with both chemotherapy and extensive debridement, and four of them required amputation. None of the eleven cases had Type IV or disseminated infection nor bacteremia.

Diagnosis of M. marinum infection is usually delayed, suggesting that most physicians are not familiar with the disease [8]. This is probably because of the rareness of the infection and a failure to establish a history of exposure to aquatic environments or to tropical fish. Key diagnostic elements for M. marinum infections are a high index of suspicion raised by negative bacterial tissue cultures, poor response to conventional antibiotic treatments, and a history of aquatic exposure [6, 18]. A definite diagnosis is confirmed by isolation and identification of the organism. All of the cases reported listed in Table 1 had positive cultures for M. marinum and the majority of the cases had history of exposure to aquatic environments.

However, in practice, the diagnosis remains largely presumptive, based on clinicohistological features and the response to appropriate antimicrobial treatment, regardless of culture results [6]. In addition, polymerase chain reaction (PCR) allows the early detection of the organism from a biopsy specimen. This technique may prove to be helpful and supersede conventional methods in the rapid diagnosis and species identification of nontuberculous infections and become the test of choice in the future [9].

Occasional spontaneous resolution of soft tissue infection by M. marinum has been reported in the literature. The main purpose of therapy aims for a rapid recovery from the infection and the prevention of progression to deeper structures [5]. Monotherapy is usually applied for skin and soft tissue infection, but this is considered ineffective for deeper structure infections. Among eleven cases with deep seated infection, only one was treated with Doxycycline monotherapy for six months (Table 2).

There have been no comparative trials of different treatment regimens for soft tissue infection by M. marinum. A literature review that was published in 2007 suggests that topical therapy as a sole treatment is completely ineffective and unnecessary [6]. In limited superficial cutaneous infections (Type I), the second-generation tetracycline minocycline (100 mg b.i.d.), clarithromycin (500 mg b.i.d.), doxycycline (100 mg b.i.d.), and trimethoprim/sulfamethoxazole (800 mg b.i.d.), each as monotherapy, are considered effective treatment options.

Based on the available literature review, a reasonable approach is to treat patient with two active antimicrobials for at least one to two months after resolution of symptoms [57]. This is more so in immunocompromised individuals and cases of severe cutaneous infections (Type II or III). Typical duration of therapy is 3-4 months. Duration of treatment is usually longer in patients with deeper structure infections [6]. Because of the extensive involvement and slow recovery, our patient treatment has been extended for nine months. In our literature review, the longest duration of therapy documented was for 18 months (Table 2).

M. marinum is usually susceptible to rifampin, rifabutin, ethambutol, clarithromycin, sulfonamides or trimethoprim/sulfamethoxazole, doxycycline, and minocycline [4, 5, 7]. In the literature, the most commonly used combinations include clarithromycin and rifampin, clarithromycin and ethambutol, or the combination of ethambutol and rifampin. In our patient, M. marinum was resistant to rifampin and unfortunately could not be used as one of the agents in the combination regimen (Table 1). However, our patient showed good response with the therapy of azithromycin and trimethoprim/sulfamethoxazole combination.

In cases with severe cutaneous infections (Types I–III), surgical treatment may be required if the infection has not been controlled by chemotherapy. Deeper infections (Type III) may require prolonged systemic treatment and repeated surgical debridement. However, the selection of cases and the time of surgical intervention require good judgment. In disseminated infection or bacteremia (Type IV), combined (antimicrobial plus antimycobacterial) intravenous therapy of three drugs may be required [6, 9, 10].

The use of isoniazid, streptomycin, and pyrazinamide as empirical treatment options should be avoided, as the resistance of the organism to these agents is well documented [6, 21]. Cryotherapy, X-ray therapy, electrodesiccation, photodynamic therapy, and local hyperthermic therapy have also been proposed as therapeutic alternatives, but there is so far no solid evidence on the successful cure rate on these [21].

In conclusion, infections due to M. marinum are uncommon, but not rare. M. marinum infection should always be included in the differential diagnosis of all cases with poorly healing wounds in upper extremities and in persons with a history of exposure to aquariums. The diagnosis requires both a detailed history and sophisticated microbiological and PCR-based investigations. No large systemic studies have been performed to determine the optimal treatment regimen. In most cases a combination of antibacterial drugs should be given as well as long-term therapy depending on the duration and severity of infection.


Dawd S. Siraj is Member of the Speaker’s Bureau for Gilead Sciences, Hepatitis Branch, and ViiV Healthcare HIV and has received honorarium for speaking.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


  1. J. D. Aronson, “Spontaneous tuberculosis in salt water fish,” The Journal of Infectious Diseases, vol. 39, no. 4, pp. 315–320, 1926. View at: Google Scholar
  2. J. A. Baker and W. A. Hagan, “Tuberculosis of Mexican platyfish (Platypoecilus maculatus),” Journal of Infectious Diseases, vol. 70, no. 3, pp. 248–252, 1942. View at: Publisher Site | Google Scholar
  3. F. Linell and A. Norden, “M. balnei: new acid fast bacillis occurring in swimming pools and capable of producing skin lesions in humans,” Acta Tuberculosea Scandinavica Journal, vol. 33, pp. 1–84, 1954. View at: Google Scholar
  4. S. J. Gluckman, “Mycobacterium marinum,” Clinics in Dermatology, vol. 13, no. 3, pp. 273–276, 1995. View at: Publisher Site | Google Scholar
  5. E. Rallis and E. Koumantaki-Mathioudaki, “Treatment of Mycobacterium marinum cutaneous infections,” Expert Opinion on Pharmacotherapy, vol. 8, no. 17, pp. 2965–2978, 2007. View at: Publisher Site | Google Scholar
  6. J. Iredell, M. Whitby, and Z. Blacklock, “Mycobacterium marinum infection: epidemiology and presentation in Queensland 1971–1990,” Medical Journal of Australia, vol. 157, no. 9, pp. 596–598, 1992. View at: Google Scholar
  7. H. Edelstein, “Mycobacterium marinum skin infections: report of 31 cases and review of the literature,” Archives of Internal Medicine, vol. 154, no. 12, pp. 1359–1364, 1994. View at: Publisher Site | Google Scholar
  8. H. W. Jolly Jr. and J. H. Seabury, “Infections with Myocbacterium marinum,” Archives of Dermatology, vol. 106, no. 1, pp. 32–36, 1972. View at: Publisher Site | Google Scholar
  9. J. R. Wendt, R. C. Lamm, D. I. Altman, H. G. Cruz, and B. M. Achauer, “An unusually aggressive Mycobacterium marinum hand infection,” Journal of Hand Surgery, vol. 11, no. 5, pp. 753–755, 1986. View at: Publisher Site | Google Scholar
  10. R. B. Clark, H. Spector, D. M. Friedman, K. J. Oldrati, C. L. Young, and S. C. Nelson, “Osteomyelitis and synovitis produced by Mycobacterium marinum in a fisherman,” Journal of Clinical Microbiology, vol. 28, no. 11, pp. 2570–2572, 1990. View at: Google Scholar
  11. J. A. Vazquez and J. D. Sobel, “A case of disseminated Mycobacterium marinum infection in an immunocompetent patient,” European Journal of Clinical Microbiology & Infectious Diseases, vol. 11, no. 10, pp. 908–911, 1992. View at: Publisher Site | Google Scholar
  12. M. Harth, E. D. Ralph, and R. Faraawi, “Septic arthritis due to Mycobacterium marinum,” Journal of Rheumatology, vol. 21, no. 5, pp. 957–960, 1994. View at: Google Scholar
  13. J. A. Alloway, S. M. Evangelisti, and J. S. Sartin, “Mycobacterium marinum arthritis,” Seminars in Arthritis and Rheumatism, vol. 24, no. 6, pp. 382–390, 1995. View at: Publisher Site | Google Scholar
  14. A. Barton, R. M. Bernstein, J. K. Struthers, and T. W. O'Neill, “Mycobacterium marinum infection causing septic arthritis and osteomyelitis,” British Journal of Rheumatology, vol. 36, no. 11, pp. 1207–1209, 1997. View at: Publisher Site | Google Scholar
  15. J. Y. Shih, P. R. Hsueh, Y. L. Chang, M. T. Chen, P. C. Yang, and K. T. Luh, “Osteomyelitis and tenosynovitis due to Mycobacterium marinum in a fish dealer,” Journal of the Formosan Medical Association, vol. 96, no. 11, pp. 913–916, 1997. View at: Google Scholar
  16. K. C. Wilson, B. Bielska, and H. W. Farber, “Mycobacterium marinum osteomyelitis,” Orthopedics, vol. 26, no. 3, pp. 331–332, 2003. View at: Google Scholar
  17. M. Sivan, D. Bose, N. Athanasou, and M. McNally, “Mycobacterium marinum osteomyelitis of a long bone,” Joint Bone Spine, vol. 75, no. 5, pp. 600–602, 2008. View at: Publisher Site | Google Scholar
  18. H. C. Tsai, S. S. J. Lee, S. R. Wann, Y. S. Chen, Y. W. Liu, and Y. C. Liu, “Mycobacterium marinum tenosynovitis: three case reports and review of the literature,” Japanese Journal of Infectious Diseases, vol. 59, no. 5, pp. 337–340, 2006. View at: Google Scholar
  19. P. Ang, N. Rattana-Apiromyakij, and C. L. Goh, “Retrospective study of Mycobacterium marinum skin infections,” International Journal of Dermatology, vol. 39, no. 5, pp. 343–347, 2000. View at: Publisher Site | Google Scholar
  20. M. A. Bhatty, D. P. Turner, and S. T. Chamberlain, “Mycobacterium marinum hand infection: case reports and review of literature,” British Journal of Plastic Surgery, vol. 53, no. 2, pp. 161–165, 2000. View at: Publisher Site | Google Scholar
  21. L. G. Adhikesavan and T. M. Harrington, “Local and disseminated infections caused by Mycobacterium marinum: an unusual cause of subcutaneous nodules,” Journal of Clinical Rheumatology, vol. 14, no. 3, pp. 156–160, 2008. View at: Publisher Site | Google Scholar

Copyright © 2015 Hao H. Nguyen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.